Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 2 selected

Type

Guidance programme 11 selected

Guidance programme

Showing 101 to 125 of 549

TitleReference numberPublishedLast updated
Difelikefalin for treating pruritus in people having haemodialysisTA890
Diabetes (type 1 and type 2) in children and young people: diagnosis and managementNG18
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapyTA886
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancerTA887
Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatmentsTA881
Voclosporin with mycophenolate mofetil for treating lupus nephritisTA882
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphomaTA883
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)TA884
Metastatic malignant disease of unknown primary origin in adults: diagnosis and managementCG104
Tezepelumab for treating severe asthmaTA880
Hypertension in pregnancy: diagnosis and managementNG133
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal)TA879
Finerenone for treating chronic kidney disease in type 2 diabetesTA877
Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancerTA876
Eptinezumab for preventing migraineTA871
Cannabidiol for treating seizures caused by tuberous sclerosis complexTA873
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphomaTA874
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapiesTA872
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myelomaTA870
Mitapivat for treating pyruvate kinase deficiency (terminated appraisal)TA867
Vutrisiran for treating hereditary transthyretin-related amyloidosisTA868
Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and managementNG231
Regorafenib for previously treated metastatic colorectal cancerTA866
Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinomaTA865
Upadacitinib for treating active non-radiographic axial spondyloarthritisTA861

Results per page

  1. 10
  2. 25
  3. 50
  4. All